PURPOSE: TRX1 is a nondepleting anti-CD4 monoclonal IgG1 antibody being developed to induce tolerance by blocking CD4-mediated functions. The purpose of this study is to describe the pharmacokinetics (PK) and pharmacodynamics (PD) of TRX1 and to develop a receptor-mediated PK/PD model that characterizes the relationships between serum TRX1 concentration and total and free CD4 expression in healthy male volunteers. METHODS: Nine subjects from three dosing cohorts in double-blinded, placebo-controlled phase I clinical study was included in the analysis. Serum TRX1 levels were determined using enzyme-linked immunosorbent assay. Blood total and free CD4 receptor levels were determined by using flow cytometric analyses. The receptor-mediated PK/PD model was developed to describe the dynamic interaction of TRX1 binding with CD4 receptors. RESULTS AND CONCLUSIONS: TRX1 displayed nonlinear pharmacokinetic behavior and the CD4 receptors on T cells were saturated and down-modulated following treatment with TRX1. Results from in vitro studies using purified human T cells suggested that CD4-mediated internalization may constitute one pathway by which CD4 is down-modulated and TRX1 is cleared in vivo. The developed receptor-mediated PK/PD model adequately described the data. This PK/PD model was used to simulate PK/PD time profiles after different dosing regimens to help guide the dose selection in future clinical studies.
PURPOSE:TRX1 is a nondepleting anti-CD4 monoclonal IgG1 antibody being developed to induce tolerance by blocking CD4-mediated functions. The purpose of this study is to describe the pharmacokinetics (PK) and pharmacodynamics (PD) of TRX1 and to develop a receptor-mediated PK/PD model that characterizes the relationships between serum TRX1 concentration and total and free CD4 expression in healthy male volunteers. METHODS: Nine subjects from three dosing cohorts in double-blinded, placebo-controlled phase I clinical study was included in the analysis. Serum TRX1 levels were determined using enzyme-linked immunosorbent assay. Blood total and free CD4 receptor levels were determined by using flow cytometric analyses. The receptor-mediated PK/PD model was developed to describe the dynamic interaction of TRX1 binding with CD4 receptors. RESULTS AND CONCLUSIONS:TRX1 displayed nonlinear pharmacokinetic behavior and the CD4 receptors on T cells were saturated and down-modulated following treatment with TRX1. Results from in vitro studies using purified human T cells suggested that CD4-mediated internalization may constitute one pathway by which CD4 is down-modulated and TRX1 is cleared in vivo. The developed receptor-mediated PK/PD model adequately described the data. This PK/PD model was used to simulate PK/PD time profiles after different dosing regimens to help guide the dose selection in future clinical studies.
Authors: C Herzog; C Walker; W Müller; P Rieber; C Reiter; G Riethmüller; P Wassmer; H Stockinger; O Madic; W J Pichler Journal: J Autoimmun Date: 1989-10 Impact factor: 7.094
Authors: A B Gottlieb; M Lebwohl; S Shirin; A Sherr; P Gilleaudeau; G Singer; G Solodkina; R Grossman; E Gisoldi; S Phillips; H M Neisler; J G Krueger Journal: J Am Acad Dermatol Date: 2000-10 Impact factor: 11.527
Authors: G P Coffey; E Stefanich; S Palmieri; R Eckert; J Padilla-Eagar; P J Fielder; S Pippig Journal: J Pharmacol Exp Ther Date: 2004-06-09 Impact factor: 4.030
Authors: J H McIntosh; M Cochrane; S Cobbold; H Waldmann; S A Nathwani; A M Davidoff; A C Nathwani Journal: Gene Ther Date: 2011-06-30 Impact factor: 5.250
Authors: Wojciech Krzyzanski; Liviawati Sutjandra; Juan Jose Perez-Ruixo; Bethlyn Sloey; Andrew T Chow; Yow-Ming Wang Journal: Pharm Res Date: 2012-12-19 Impact factor: 4.200